Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $12.00 by Analysts at HC Wainwright

Y-mAbs Therapeutics (NASDAQ:YMAB) had its target price cut by HC Wainwright from $22.00 to $12.00 in a research note published on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Other analysts also recently issued reports about the company. Truist Financial dropped their price objective on Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, March 5th. Wedbush restated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Morgan Stanley lowered their price objective on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a research report on Wednesday, March 5th. Bank of America cut their target price on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. Finally, Brookline Capital Management initiated coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 price target for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $18.30.

Y-mAbs Therapeutics Stock Up 1.6 %

NASDAQ YMAB opened at $5.00 on Friday. The firm has a 50-day moving average price of $5.71 and a two-hundred day moving average price of $9.83. The company has a market capitalization of $226.09 million, a P/E ratio of -9.26 and a beta of 0.65. Y-mAbs Therapeutics has a 12-month low of $4.25 and a 12-month high of $17.78.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The firm had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. During the same period last year, the business earned ($0.02) earnings per share. Equities analysts expect that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Insider Activity at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 10,810 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the sale, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. This represents a 5.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 22.50% of the stock is currently owned by company insiders.

Institutional Trading of Y-mAbs Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Y-mAbs Therapeutics during the 3rd quarter worth about $44,000. KLP Kapitalforvaltning AS acquired a new stake in Y-mAbs Therapeutics during the 4th quarter worth about $46,000. ProShare Advisors LLC acquired a new stake in Y-mAbs Therapeutics during the 4th quarter worth about $99,000. Intech Investment Management LLC acquired a new stake in Y-mAbs Therapeutics during the 3rd quarter worth about $133,000. Finally, Wells Fargo & Company MN grew its holdings in Y-mAbs Therapeutics by 54.1% during the 4th quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock worth $137,000 after acquiring an additional 6,131 shares during the period. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.